Efficacy and safety of a nano-emulsion gel formulation of adapalene 0.1% and clindamycin 1% combination in acne vulgaris: A randomized, open label, active-controlled, multicentric, phase IV clinical trial

Indian Journal of Dermatology, Venereology and Leprology

Volumn 78, Issue 4, 2012, Pages 459-467

  Prasad, Siva ^a   Mukhopadhyay, Amiya ^b   Kubavat, Amit ^c   Kelkar, Amit ^d   Modi, Ajay ^e   Swarnkar, Bhavesh ^f   Bajaj, Bobby ^g   Vedamurthy, Maya ^h   Sheikh, Shafiq ^c   Mittal, Ravindra ^c  

^a Skin Care Centre   (India)

^b Dr Amiya Mukhopadhyay's Skin Clinic   (India)

^c ZYDUS RESEARCH CENTRE   (India)

^d Dr Kelkar's Skin Clinic   (India)

^e Twacha Skin Care and Laser Centre   (India)

^f Swarnkar Skin Centre   (India)

^g Bajaj Medicine and Skin Clinic   (India)

^h RSV Skin Clinic   (India)

Author keywords

Acne; adapalene; clindamycin; clinical trial; India; nano emulsion

Indexed keywords

ADALENE NANOGEL; ADAPALENE; ADAPALENE PLUS CLINDAMYCIN; CLINDAMYCIN; DERIVA CMS NANOGEK; UNCLASSIFIED DRUG;

ACNE VULGARIS; ADOLESCENT; ADULT; APPLICATION SITE DRYNESS; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PHOTOSENSITIVITY REACTION; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NANOEMULSION; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; EMULSIONS; FEMALE; GELS; HUMANS; MALE; NANOTECHNOLOGY; NAPHTHALENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864247540     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.98077     Document Type: Article

References (27)

1. Magin P, Adams J, Heading G, Pond D, Smith W. Psychological sequelae of acne vulgaris: Results of a qualitative study. Can Fam Physician 2006;52:978-9.
2. Kokandi A. Evaluation of acne quality of life and clinical severity in acne female adults. Dermatol Res Pract 2010;2010:pii: 410809. 3 pages. Article ID: 410809. doi:10.1155/2010/410809. Cited in PubMed; PMID 20706683. Available at: http://www.hindawi.com/journals/drp. Accessed June 6, 2011.
3. Dunn LK, O'Neill JL, Feldman SR. Acne in adolescents: Quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J 2011;17:1. about 10 pages Article ID: 1. Cited in PubMed; PMID 21272492. Available at: http://dermatology.cdlib.org. Accessed June 6, 2011.
4. Al Robaee AA. Assessment of general health and quality of life in patients with acne using a validated generic questionnaire. Acta Dermatovenerol Alp Panonica Adriat 2009;18:157-64.
5. Adityan B, Thappa DM. Profile of acne vulgaris-a hospital-based study from South India. Indian J Dermatol Venereol Leprol 2009;75:272-8.
6. Friedlander SF, Eichenfield LF, Fowler JF Jr, Fried RG, Levy ML, Webster GF. Acne epidemiology and pathophysiology. Semin Cutan Med Surg 2010;29:2-4.
7. Thiboutot D, Gollnick H, Bettoli V, Drno B, Kang S, Leyden JJ, et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009;60:S1-50.
8. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49:S1-37.
9. Thielitz A, Abdel-Naser MB, Fluhr JW, Zouboulis CC, Gollnick H. Topical retinoids in acne-an evidence-based overview. J Dtsch Dermatol Ges 2008;6:1023-31.
10. Irby CE, Yentzer BA, Feldman SR. A review of adapalene in the treatment of acne vulgaris. J Adolesc Health 2008;43:421-4.
11. Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis 2010;85:15-24.
12. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005;153:395-403.
13. Jain GK, Ahmed FJ. Adapalene pretreatment increases follicular penetration of clindamycin: In vitro and in vivo studies. Indian J Dermatol Venereol Leprol 2007;73:326-9.
14. Wolf JE Jr, Kaplan D, Kraus SJ, Loven KH, Rist T, Swinyer LJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003;49:S211-7.
15. Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004;15:372-8.
16. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006;54:73-81.
17. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008;59:792-800.
18. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007;66: 227-43.
19. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J Nanobiotechnology 2008;6:8. 11 pages. Article ID: 8. doi:10.1186/1477-3155-6-8. Cited in PubMed; PMID 18613981. Available at: http://www.jnanobiotechnology.com. Accessed June 6, 2011.
20. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech 2007;8:E104. 9 pages Article ID: 104. doi:10.1208/pt0804104. Cited in PubMed; PMID 18181525. Available at: www.aapspharmscitech.org. Accessed June 6, 2011.
21. Leyden JJ, Ijzerman MM, Flack MR, Baker Jr. Evaluation of the safety and efficacy of a novel anti-acne nanoemulsion (NB-003) in a randomized, open-label, parallel-group, single center study. Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2010 Sep 12-15; Boston, U.S.A. Available at: http://www.nanobio.com/news/documents/ICAAC-2010- L1-1751-Acne.pdf. Accessed June 6, 2011.
22. Ciotti S, Eisma R, Pannu J, McCarthy A, Baker Jr. Novel Follicular-Targeted Nanoemulsions for Acne. Proceedings of Summer Academy Meeting 2009; 2009 Jul 29-Aug 2; Boston, U.S.A. Available at: http://www.nanobio.com/documents/AAD-Summer-P109-Follicular-Targeted-NE-Acne. pdf. Accessed June 6, 2011.
23. Pannu J, Ciotti S, Eisma R, Ma L, Sutcliffe J. In vitro Susceptibility of Propionibacterium acnes and Skin Permeation of NB-00X Formulations. Proceedings of the 69th Annual Meeting of Society for Investigative Dermatology; 2009 May 6-9; Montreal, Canada. Available at: http://www.nanobio.com/news/documents/ 148098-616-11x17.pdf. Accessed June 6, 2011.
24. Pannu J, McCarthy A, Martin A, Sutcliffe J. Susceptibility of Propionibacterium acnes in the Presence of Sebum to NB-003 Formulations. Proceedings of Summer Academy Meeting 2009; 2009 Jul 29-Aug 2; Boston, U.S.A. Available at: http://www.nanobio.com/documents/AAD-Summer-P106-Susceptibility-P- acnes-Sebum.pdf. Accessed June 6, 2011.
25. Sonneville-Aubrun O, Simonnet JT, L'Alloret F. Nanoemulsions: A new vehicle for skincare products. Adv Colloid Interface Sci 2004;108-109:145-9.
26. Zaghloul SS, Cunliffe WJ, Goodfield MJ. Objective assessment of compliance with treatments in acne. Br J Dermatol 2005;152:1015-21.
27. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics 2006;118:1188-99.